Dynavax Reports Third Quarter 2015 Financial Results

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Dynavax Reports Third Quarter 2015 Financial Results

BERKELEY, CA--(Marketwired - Nov 5, 2015) - Dynavax Technologies Corporation ( NASDAQ : DVAX ) today reported financial results for the third quarter ended September 30, 2015.

The Company had $220.7 million in cash, cash equivalents and marketable securities as of September 30, 2015, compared to $93.4 million at June 30, 2015. The balance at September 30, 2015 includes approximately $164 million of net proceeds from sales of common stock in the third quarter and reflects payment of all principal and accrued interest, prepayment charges and other fees totaling approximately $11 million under a loan agreement.

Operating expenses of $29.6 million for the quarter ended September 30, 2015 increased by $4.8 million compared to the quarter ended June 30, 2015 primarily due to production, clinical trial and commercial preparation costs.

We recently initiated a clinical trial to evaluate the combination of our cancer immunotherapeutic product candidate SD-101 and Merck's KEYTRUDA ® (pembrolizumab) in patients with metastatic melanoma. All study visits for HBV-23, the Phase 3 clinical study of HEPLISAV-B™, were completed in October 2015. Top line results of this study are expected to be released in early 2016. 

The net loss allocable to common stockholders for the quarter ended September 30, 2015 was $30.1 million, or $0.82 per basic and diluted share. The net loss allocable to common stockholders for the quarter ended June 30, 2015 was $23.6 million, or $0.80 per basic and diluted share.

About Dynavax

Dynavax, a clinical-stage biopharmaceutical company, uses TLR biology to discover and develop novel vaccines and therapeutics in the areas of infectious and inflammatory diseases and oncology. Dynavax's lead product candidates are HEPLISAV-B, a Phase 3 investigational adult hepatitis B vaccine, and SD-101, an investigational cancer immunotherapeutic currently in several Phase 1/2 studies. For more information visit www.dynavax.com .

Forward Looking Statements

This release contains forward-looking statements, including statements regarding expected timing of results from HBV-23. These statements are subject to a number of risks and uncertainties that could cause actual results to differ materially, including whether HBV-23 can be completed as expected, whether the endpoints of the study will be achieved and the final results otherwise be satisfactory, whether successful development and approval of HEPLISAV-B and our process for its manufacture can occur in a timely manner or without significant additional studies or difficulties or delays; whether clinical studies for our products can be enrolled, supplied and completed in a timely manner and will be sufficient for further development or for marketing approval; the potential size and value of approved indications addressable with HEPLISAV-B and the commercial potential for HEPLISAV-B; initiation and completion of pre-clinical studies and clinical trials of our other product candidates; the results of clinical trials and the impact of those results on the initiation or continuation of subsequent trials and issues arising in the regulatory process; achieving the objectives of and maintaining our collaborative and licensing agreements; our ability to execute on our commercial strategies; whether our financial resources will be adequate without the need to obtain additional financing and other risks detailed in the "Risk Factors" section of our most recent current periodic report filed with the SEC. These statements represent our estimates and assumptions only as of the date of this presentation. We do not undertake any obligation to update publicly any such forward-looking statements, even if new information becomes available.

- tables to follow -

   
DYNAVAX TECHNOLOGIES CORPORATION  
CONSOLIDATED STATEMENTS OF OPERATIONS  
(In thousands, except per share amounts)  
(Unaudited)  
   
  Three Months Ended September 30,     Nine Months Ended September 30,  
  2015     2014     2015     2014  
Revenues:                              
  Collaboration revenue $ 829     $ 1,795     $ 2,230     $ 6,199  
  Grant revenue   359       414       608       2,546  
  Service and license revenue   -       -       527       10  
Total revenues   1,188       2,209       3,365       8,755  
                               
Operating expenses:                              
  Research and development   24,105       28,072       66,011       64,942  
  General and administrative   5,524       4,083       15,481       12,325  
  Unoccupied facility expense   -       131       -_       386  
Total operating expenses   29,629       32,286       81,492       77,653  
                               
Loss from operations   (28,441 )     (30,077 )     (78,127 )     (68,898 )
                               
Interest income   33       42       78       162  
Interest expense   (62 )     -       (572 )     -  
Other income, net   17       216       360       300  
Loss on extinguishment of debt   (1,671 )     -       (1,671 )     -  
                               
Net loss $ (30,124 )   $ (29,819 )   $ (79,932 )   $ (68,436 )
                               
Basic and diluted net loss per share $ (0.82 )   $ (1.13 )   $ (2.43 )   $ (2.60 )
                               
Shares used to compute basic and diluted net loss per share   36,532       26,291       32,880       26,288  
                               
                               
                               
DYNAVAX TECHNOLOGIES CORPORATION
SELECTED BALANCE SHEET DATA
(In thousands)
 
  September 30,   December 31,
  2015   2014
  (unaudited)    
Assets          
  Cash, cash equivalents and marketable securities $ 220,697   $ 122,652
  Property and equipment, net   11,606     7,924
  Goodwill   2,106     2,277
  Other assets   4,498     5,437
Total assets $ 238,907   $ 138,290
           
Liabilities and stockholders' equity          
  Deferred revenues $ 10,546   $ 12,765
  Other liabilities   17,173     15,484
  Long-term debt   -     9,559
  Total liabilities   27,719     37,808
  Stockholders' equity   211,188     100,482
Total liabilities and stockholders' equity $ 238,907   $ 138,290
           

Contact: Michael Ostrach Chief Financial Officer 510-665-7257 Email Contact

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Kinross Lawsuit Puts Round Mountain Claims Under Fire

Updated Category News Views 94

A mine can swallow a rosy forecast faster than any spreadsheet admits. That is the ugly center of the proposed securities class action involving Kinross Gold: not merely that production guidance came down, but the allegation that investors were sold too much confidence before the operational reality at Round Mountain Phase S surfaced. NYSE:KGC dropped from $27.62 on...

Continue Reading
Allooloo's 100M Calls Test Capital Markets AI Data

Updated Category News Views 209

Forty-one point nine thousand issuers is a lot of financial clutter to keep straight, and Allooloo says its machines are getting called on to do precisely that at industrial scale. The Vancouver-based company reported on November 20 that its capital-markets data products now receive 100 million AI-agent calls a month—roughly 3.4 million daily, or 39 per second. That is...

Continue Reading
Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 17

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading
Cottage Grove Tests Holiday Demand Across Lake Norman

Updated Category News Views 139

Flour and foot traffic make a pretty honest little scoreboard. Cottage Grove Bakery is putting itself in front of Lake Norman shoppers twice on Saturday, November 21, while also taking Thanksgiving orders and laying groundwork for 2027 workplace and school visits. This is not a public-company earnings story, and nobody should pretend a tray of scones is a quarterly...

Continue Reading
Domino's Probe Puts Franchise Disclosure Under Lens

Updated Category News Views 139

A franchisee's shuttered stores can turn cheerful unit-growth talk into a nasty accounting of credibility, and that is the uncomfortable territory Domino's now occupies. Kahn Swick & Foti has opened an investigation into whether Domino's officers and directors breached fiduciary duties or violated state or federal law. That is not a finding of misconduct. It is a legal...

Continue Reading
Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 94

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading
ModuleMD Takes Allergy EHR AI Beyond the Usual Hype Cycle

Updated Category News Views 203

Allergy Workflows Are Where This Has to Earn Its Keep Allergy clinics do not need another shiny dashboard clogging up a workstation. They need less typing, fewer handoffs, cleaner documentation, and fewer administrative chores slipping through the cracks while a packed day keeps moving. That is the practical lens for ModuleMD's ACAAI 2026 presentation in Phoenix: not...

Continue Reading
Employer Ghosting Is a Quiet Talent-Cost Problem Today

Updated Category News Views 97

Silence is cheap right up until a company needs talent again. Then the unanswered email, abandoned interview loop, or vanished promise of next steps comes back with a price tag—maybe not neatly labeled in a quarterly filing, but real all the same. LiveCareer’s April 14, 2026 survey of 1,008 employed U.S. adults lands on an uncomfortable point: candidates remember...

Continue Reading
California Initiative Puts Missed Diagnoses in Focus

Updated Category News Views 167

When Reassurance Turns Into a Risk A clean scan can become a dangerous lullaby when symptoms refuse to leave. That is the hard, unsettling territory behind Hodes Milman’s new Missed Diagnosis Project: California, launched November 20, 2026. The statewide effort focuses on breast cancer diagnostic failures: scans read as benign when more scrutiny was warranted, referrals...

Continue Reading
Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 58

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading

Top 5 Most Recently Viewed Articles

Strategies for Trading Key Stocks: SPY, AAPL & More

Updated Category News Views 72

Morning Trading Insights for Major Stocks Good Morning Traders! In today's Market Clubhouse Morning Memo, we'll take a closer look at key stocks such as SPY, QQQ, AAPL, MSFT, NVDA, GOOGL, META, and TSLA. Keeping an eye on these stocks could be crucial for your trading strategy today. Using our proprietary formula exclusive to Market Clubhouse, we determine price levels...

Continue Reading
Precious Metals Shine as Gold Miners Show Strong Growth

Updated Category News Views 194

Gold Miners Surge Ahead of Broader Metals Market The precious metals sector is currently thriving, with gold miners exhibiting significant growth and surpassing previous resistance levels. This encouraging trend is apparent as the GDX index, which tracks the performance of gold mining companies, continues its upward trajectory. Comparison of Junior and Regular Miners...

Continue Reading
MacGregor Revamps Fleet for Wallenius Wilhelmsen Deal

Updated Category News Views 207

MacGregor's Big Move: Retrofitting 35 Vessels I'll tell you something right off the bat—the maritime industry's always got some sea changes brewing, but this latest one’s a real head-turner. MacGregor, those wizards of heavy machinery, have sealed a deal to retrofit 35 ships for Wallenius Wilhelmsen. We’re talking a serious overhaul here, folks, with programmable...

Continue Reading
Nokia Corporation Announces Share Transfer for Incentive Plans

Updated Category News Views 207

Nokia Corporation's Recent Share Transfers Nokia Corporation has recently made significant changes involving its own shares, reflecting its ongoing commitment to its equity-based incentive plans. A total of 5,348 Nokia shares (Helsinki:NOKIA) were transferred today to participants of these plans, emphasizing the company's engagement with its employees and stakeholders....

Continue Reading
Director Peter Hammond Acquires Shares in Adsure Services PLC

Updated Category News Views 271

Director's Share Purchase Signals Confidence In a notable move reflecting confidence in future growth, Adsure Services PLC (LSE:ADS) revealed that director Peter John Hammond has acquired 29 ordinary shares priced at £0.21 each. This acquisition has drawn attention due to its nature as a notification under the UK Market Abuse Regulation guidelines. Details of the...

Continue Reading